Hercules Capital

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing novel therapies for inflammatory skin and joint diseases. Its flagship product, SLK, is an investigational Nanobody targeting IL-17A and IL-17F, showing potential for disease modification in dermatology and rheumatology patients.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Adaptimmune Therapeutics is a biopharmaceutical company focused on developing novel cell therapies to treat solid tumors. It employs its proprietary SPEAR T-cell platform to identify cancer targets and generate therapeutic candidates for clinical trials.

SynOx Therapeutics is a biopharmaceutical company focused on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Incorporated in 2019, the company is based in Dublin, Ireland.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic respiratory diseases with unmet medical needs. Its lead candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterases 3 and 4 that provides bronchodilation and anti-inflammatory effects in a single molecule. Development programs include formulations of ensifentrine for chronic obstructive pulmonary disease, with options such as nebulized administration, a dry powder inhaler, and a pressurized metered-dose inhaler. Verona Pharma is also pursuing development of ensifentrine for cystic fibrosis and asthma. The company was founded in 2005 and is headquartered in London, United Kingdom.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.

Founded in 2021, AmplifyBio is a biotechnology company headquartered in West Jefferson, OH. It specializes in developing next-generation cell and gene therapies, with a mission to advance medical breakthroughs and treatments for diseases.

Kura Oncology is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer patients. Its pipeline comprises small molecule drug candidates targeting specific cancer signaling pathways, with a focus on solid tumors and hematologic malignancies.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Akero Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, with a primary emphasis on nonalcoholic steatohepatitis (NASH). Its lead program is a long-acting fibroblast growth factor 21 (FGF21) analog designed to restore metabolic balance and address liver fat, inflammation, and fibrosis. The company was founded in 2017 and is headquartered in South San Francisco, California.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic and liver diseases, including cardiovascular-metabolic conditions and metabolic dysfunction-associated steatohepatitis. The company’s lead drug, resmetirom, is an oral liver-directed thyroid hormone receptor beta agonist advancing in late-stage trials for non-alcoholic steatohepatitis. Madrigal is pursuing additional THR-beta agonists in preclinical development to address NASH and related dyslipidemia, and maintains collaborations to develop and commercialize licensed products, including with Hoffmann-La Roche. The company targets broader cardiovascular-metabolic diseases such as diabetes and dyslipidemia. Founded in 2011, Madrigal is headquartered in West Conshohocken, Pennsylvania.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its lead therapies include Umbralisib (PI3K delta and CK1 epsilon inhibitor) for NHL and CLL, Ublituximab (CD20-targeting antibody) for NHL, CLL, and MS, Cosibelimab (PD-L1 inhibitor), TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific antibody). The company has strategic alliances with several pharmaceutical companies and generates revenue primarily in the United States.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Corium International is a biopharmaceutical company focused on the development, manufacture, and commercialization of transdermal and transmucosal drug delivery systems. Its products span indications such as hypertension (clonidine TDS) and chronic pain management (fentanyl TDS), and include Crest Whitestrips for teeth whitening. The company is advancing a pipeline across neurological and systemic therapies, including a combination hormonal contraceptive patch (Twirla), transdermal therapies for osteoporosis (hPTH(1-34)) and Alzheimer's disease (donepezil and memantine TDS), as well as patches for psychiatric disorders (aripiprazole), Parkinson's disease (Corplex ropinirole), and motion sickness. Corium also collaborates with leading pharma groups such as Procter & Gamble, Teva, Agile Therapeutics, and Aequus. Founded in 1995 and headquartered in Menlo Park, California, Corium aims to simplify delivery and enhance safety and adherence through its proprietary transdermal and transmucosal platforms.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Novelion Therapeutics Inc. is a biopharmaceutical company based in Vancouver, Canada, focused on developing therapies for individuals with rare diseases. The company offers commercial products, including metreleptin, which treats complications of leptin deficiency in patients with generalized lipodystrophy, marketed under the MYALEPTA brand, and lomitapide capsules for adult patients with homozygous familial hypercholesterolemia, sold as JUXTAPID and LOJUXTA. Novelion also invests in the development of innovative therapies, including zuretinol acetate for treating inherited retinal diseases linked to mutations in specific genes. Originally founded in 1981 as QLT Inc., the company rebranded to Novelion Therapeutics in 2016 and operates through its subsidiary, Aegerion Pharmaceuticals, which is dedicated to addressing the needs of patients with debilitating rare diseases.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections in the United States and internationally. Its lead product candidate, ibrexafungerp, is being developed as both an oral and intravenous treatment for various fungal infections, including vulvovaginal candidiasis and invasive aspergillosis. Ibrexafungerp has successfully completed Phase 2 clinical trials for its indication in vulvovaginal candidiasis. The company collaborates with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to advance the development and commercialization of ibrexafungerp. In addition to its antifungal focus, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials and oncology, and offers contract research solutions such as medicinal chemistry and process development. Originally founded in 1999 and known as SCYNEXIS Chemistry & Automation, Inc., the company rebranded to SCYNEXIS, Inc. in June 2002 and is headquartered in Jersey City, New Jersey.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory disorders, autoimmune diseases, and cancer. It focuses on orally-administered small molecule therapeutics targeting chemokine receptors.

Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing next-generation medicines to address immune-mediated and metabolic diseases. Its lead program Reproxalap is in late-stage development for dry eye disease and allergic conjunctivitis, with additional candidates targeting retinal and systemic inflammatory conditions. The company maintains a broader portfolio that includes compounds such as ADX248, ADX743, ADX631, ADX246, ADX629, and ADX2191, and is exploring therapies for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, Sjögren-Larsson Syndrome, other retinal diseases, autoimmune diseases, and cancer.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its lead therapies include Umbralisib (PI3K delta and CK1 epsilon inhibitor) for NHL and CLL, Ublituximab (CD20-targeting antibody) for NHL, CLL, and MS, Cosibelimab (PD-L1 inhibitor), TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific antibody). The company has strategic alliances with several pharmaceutical companies and generates revenue primarily in the United States.

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for urologic conditions. Its lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH), and pain associated with irritable bowel syndrome (IBS). The company's second investigational product candidate, URO-902, is a novel gene therapy for patients with OAB symptoms who have failed oral pharmacologic therapy.

Mesoblast develops and commercializes allogeneic cellular medicines derived from its proprietary mesenchymal lineage adult stem cell platform. Its product pipeline focuses on areas such as cardiovascular diseases, orthopedic disorders, oncology, hematology, and immune-mediated conditions. Key products include Ryoncil for steroid-refractory acute graft versus host disease and Revascor for chronic heart failure.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Founded in 1993, Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on discovering, designing, and developing therapies for diseases, particularly in the areas of autoimmunity and cancer.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Exicure, founded in 2011 and headquartered in Chicago, Illinois, is a clinical-stage biotechnology company specializing in the development of therapeutics using its proprietary spherical nucleic acid (SNA) technology. Its pipeline includes AST-008 for advanced solid tumors, XCUR-FXN for Friedreich’s ataxia, and XCUR17 targeting interleukin 17 receptor alpha. Exicure has collaborations with Allergan Pharmaceuticals International Limited and DERMELIX, LLC.

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health and endocrine diseases. Founded in 2016 and based in Brisbane, California, the company’s lead product is relugolix, an oral, once-daily gonadotropin-releasing hormone receptor antagonist designed to treat heavy menstrual bleeding associated with uterine fibroids, endometriosis-related pain, and advanced prostate cancer. Myovant is also developing MVT-602, a kisspeptin agonist aimed at addressing female infertility within assisted reproduction. The company has established a collaboration with Pfizer Inc. to advance the development and commercialization of relugolix in both oncology and women's health. Myovant Sciences was previously known as Roivant Endocrinology Ltd. before changing its name in May 2016.

BioQ Pharma Incorporated is a specialty pharmaceutical company that develops and commercializes a range of ready-to-use infusible pharmaceuticals, focusing on post-surgical pain management, anesthesia, and sedation. The company offers products such as Ropivacaine for pain relief and Propofol for anesthesia, while also working on pipeline candidates in antibiotics and oncology. BioQ Pharma utilizes a proprietary unit-dose infusion system designed to enhance the efficiency, safety, and sterility of medication administration at the point of care. This innovative approach aims to address critical issues in infusion therapy, including medication errors and cost-effectiveness, ultimately improving patient quality of life. The company markets its products through partnerships in the U.S., Europe, China, and Taiwan, collaborating with notable firms in the pharmaceutical industry. Established in 2003 and based in San Francisco with an additional site in Gent, Belgium, BioQ Pharma was formerly known as BioQuiddity Incorporated until its name change in 2015.

Concert Pharmaceuticals is a clinical‑stage biopharmaceutical company headquartered in Lexington, Massachusetts, founded in 2006. The company develops small‑molecule therapies for autoimmune and central nervous system disorders using a precision deuterium chemistry platform that modifies drug molecules to improve efficacy, safety, and reduce development risk. Its pipeline includes CTP‑543, a Phase III candidate for alopecia areata; CTP‑692, a Phase II candidate for schizophrenia; and AVP‑786, a Phase III combination therapy for neurologic and psychiatric conditions such as agitation in Alzheimer’s disease. Concert collaborates with Avanir, Cipla Technologies, Processa, and Jazz Pharmaceuticals to advance its candidates. The firm focuses on orally administered agents and repurposed drugs for conditions including cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer’s agitation.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Sio Gene Therapies, Inc. is a clinical-stage gene therapy company dedicated to developing innovative treatments for debilitating neurodegenerative diseases. The company is advancing several clinical programs, including AXO-Lenti-PD for Parkinson's disease, AXO-AAV-GM1 for GM1 gangliosidosis, and AXO-AAV-GM2 for GM2 gangliosidosis. Founded in 2014 and headquartered in New York, Sio Gene Therapies leverages extensive scientific expertise and strategic partnerships with leading gene therapy institutions to enhance its research and development efforts. Formerly known as Axovant Gene Therapies, the company rebranded in November 2020 to better reflect its mission and focus on transforming patient care through gene therapy.

Mast Therapeutics is a biopharmaceutical company based in San Diego that specializes in developing proprietary product candidates aimed at treating serious or life-threatening diseases with significant unmet medical needs. The company focuses on novel, clinical-stage therapies for various conditions, including respiratory diseases, sickle cell disease, and heart failure. By targeting these areas, Mast Therapeutics seeks to provide innovative treatment options for patients who currently lack effective therapies.

CytRx Corporation is a biopharmaceutical company based in Los Angeles, California, that specializes in the research and development of oncology treatments and therapies for rare diseases. The company's primary focus is on the clinical development of aldoxorubicin, an improved formulation of the widely used chemotherapeutic agent doxorubicin, which is designed to enhance drug delivery to tumors. CytRx is advancing multiple clinical trials, including a Phase 2b trial for soft tissue sarcomas and other investigations involving metastatic solid tumors. The company leverages innovative linker technologies to create drug candidates that promote targeted release of cytotoxic agents at tumor sites. In addition to aldoxorubicin, CytRx holds rights to other drug candidates, including tamibarotene and bafetinib, and has developed an albumin companion diagnostic product to identify suitable patients for treatment. Founded in 1985, CytRx continues to expand its oncology pipeline, aiming to improve treatment outcomes for cancer patients.

Zosano Pharma is a clinical-stage biopharmaceutical company developing therapeutics with a proprietary transdermal microneedle delivery system that enables rapid systemic administration of drugs. It focuses on migraine treatments, with its lead candidate Qtrypta (M207), a zolmitriptan formulation designed for quick relief. Founded in 2006 and headquartered in Fremont, California, Zosano aims to improve how migraine therapies are delivered by combining innovative drug delivery technology with clinically meaningful products.

The AspireAssist™ is a breakthrough weight loss solution for people with obesity. Unlike many other weight loss procedures, it's minimally-invasive and reversible. The AspireAssist is now commercially available in selected regions in Europe and beyond, and is currently in clinical trials across the US.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, dedicated to the development of novel cellular immunotherapies for treating various cancers, including hematological malignancies and solid tumors. The company is advancing its innovative product candidates, notably BPX-601, an autologous GoCAR-T therapy targeting solid tumors that express prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy aimed at tumors expressing human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control over immune system components, enhancing the efficacy and duration of therapeutic responses. Founded in 2004, Bellicum Pharmaceuticals has established collaborations with several organizations to further its research and development efforts in immunotherapy.

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Gamma Medica, Inc. specializes in advanced digital molecular imaging devices aimed at the early detection of breast cancer in women. The company offers the LumaGEM® MBI System, which is notable for being the first FDA-cleared, planar, dual head, fully solid state digital imaging system utilizing cadmium zinc telluride (CZT) technology. This system is particularly effective in identifying millimeter-sized breast cancers that may be missed by traditional mammography, especially in patients with dense breast tissue. In addition to LumaGEM, Gamma Medica provides a range of imaging technologies, including digital X-ray mammography, tomography, 3D mammography, and ultrasound systems, all designed to enhance screening capabilities and facilitate early intervention for breast cancer.

Gamma Medica, Inc. specializes in advanced digital molecular imaging devices aimed at the early detection of breast cancer in women. The company offers the LumaGEM® MBI System, which is notable for being the first FDA-cleared, planar, dual head, fully solid state digital imaging system utilizing cadmium zinc telluride (CZT) technology. This system is particularly effective in identifying millimeter-sized breast cancers that may be missed by traditional mammography, especially in patients with dense breast tissue. In addition to LumaGEM, Gamma Medica provides a range of imaging technologies, including digital X-ray mammography, tomography, 3D mammography, and ultrasound systems, all designed to enhance screening capabilities and facilitate early intervention for breast cancer.

Edge Therapeutics is a clinical-stage biotechnology company based in Berkeley Heights, New Jersey, focused on developing innovative therapies for acute, life-threatening neurological conditions. Established in 2009, the company aims to transform treatment paradigms in hospital settings through its proprietary platform, Precisa, which facilitates the creation of polymer-based therapeutics designed for targeted delivery to injury sites. The lead product candidate, EG-1962, is currently undergoing evaluation in the Phase 3 NEWTON 2 study, aimed at improving outcomes for patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). Additionally, Edge is assessing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aimed at preventing recurrent bleeding on the brain's surface. Through these efforts, Edge Therapeutics seeks to address serious unmet medical needs in the field of neurology.

uniQure is a pioneering gene therapy company recognized for developing the first gene therapy product to receive regulatory approval in the European Union. Its initial product, Glybera, was authorized in October 2012 for treating patients with lipoprotein lipase deficiency, a rare and severe metabolic disorder. uniQure specializes in creating innovative gene therapies that offer long-term and potentially curative benefits for genetic and acquired diseases. The company utilizes a modular technology platform and a proprietary manufacturing process to develop its treatments. Currently, uniQure is expanding its pipeline of adeno-associated virus (AAV)-based gene therapies, focusing on conditions such as hemophilia, Huntington's disease, and cardiovascular diseases through collaborations, including one with Bristol Myers Squibb. While the company initially targets orphan diseases, it also aims to address chronic and degenerative diseases affecting larger populations.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

CTI BioPharma Corp. is a biopharmaceutical company headquartered in Seattle, Washington, that specializes in the acquisition, development, and commercialization of targeted therapies for blood-related cancers. Founded in 1991 and formerly known as Cell Therapeutics, Inc., the company is primarily focused on developing novel treatments to improve patient outcomes in oncology. Its key investigational product, pacritinib, is an oral kinase inhibitor currently in Phase III clinical trials for the treatment of myelofibrosis in adults. In addition to pacritinib, CTI BioPharma's portfolio includes other candidates like Pixantrone, which is undergoing Phase III trials for non-Hodgkin's lymphoma, and Brostallicin, currently in a Phase II study for sarcoma. The company has established collaboration and licensing agreements with several pharmaceutical partners.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Imunon is a clinical-stage biotechnology company focused on advancing innovative cancer treatments. Its portfolio includes immunotherapies and DNA-based therapies, with a key product being GEN-1, a DNA-based immunotherapy for localized ovarian cancer treatment.

Cleveland BioLabs, Inc. is a biopharmaceutical company focused on developing innovative treatments to activate the immune system and address significant medical challenges, particularly in oncology and radiation protection. Established in 2003 and based in Buffalo, New York, the company utilizes its proprietary platform of toll-like receptor (TLR) activators to create products aimed at mitigating radiation injuries and enhancing cancer therapies. Its lead product candidate, entolimod, serves as an immune-stimulatory agent for both radiation countermeasures and various oncology applications. Additionally, Cleveland BioLabs is developing Mobilan, a recombinant non-replicating adenovirus that targets TLR5. The company collaborates with esteemed institutions such as the Cleveland Clinic and Roswell Park Cancer Institute to advance its research and development initiatives.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

Fortress Biotech is a biopharmaceutical company focused on acquiring, developing, and commercializing marketed drugs and development-stage candidates. With over 25 programs in its pipeline, the company concentrates on therapeutic areas such as oncology, rare diseases, gene and cell therapy.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for serious diseases, particularly those associated with inflammation, including cardiovascular and autoimmune conditions. Founded in 2004 and headquartered in Hayward, California, the company is advancing several product candidates. Its notable projects include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for exocrine pancreatic insufficiency, and Blisibimod, which is undergoing Phase II trials for B-cell mediated autoimmune diseases such as IgA nephropathy. Anthera also develops varespladib methyl and varespladib sodium, both of which are in various stages of clinical trials for acute coronary syndrome and sickle cell disease, respectively. The company has established license agreements with major pharmaceutical firms, including Amgen and Eli Lilly, to enhance its development and commercialization efforts.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Chroma Therapeutics Ltd., established in 2000, is a privately-held biotechnology company based in Abingdon, UK. It specializes in developing novel small molecule drugs for targeted cancer and inflammation treatments, drawing from chromatin biology and innovative cell accumulation approaches. The company's pipeline includes Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for cancer treatment; and CHR-2845, a targeted solution for hematological malignancies. Chroma has built a strong network of academic collaborators and holds the first systematic assembly of intellectual property in chromatin biology, aiming to create substantial shareholder value through its innovative product pipeline targeting high-prevalence diseases.

PolyMedix is a development-stage biotechnology company focused on therapies for acute cardiovascular disorders and infectious diseases. It uses proprietary computational drug design to create synthetic small-molecule compounds that imitate the activity of large natural protein molecules, aiming to enable novel treatments and innate-immunity modifiers. The company develops products in clinical and preclinical stages, including heparin antagonist agents and broad-spectrum antibiotics, and maintains programs spanning anti-tuberculosis, anti-malaria, anti-fungal compounds, bio-defense products, angiogenesis inhibitors, and polymer biomaterials. Founded in 2002 and based in Radnor, Pennsylvania, PolyMedix pursues a portfolio of drug candidates intended to address urgent medical needs.

Kamada is a biopharmaceutical company that develops, produces, and markets specialty life-saving therapeutics using proprietary protein purification technology. Its product portfolio includes Glassia for Alpha-1 Antitrypsin deficiency treatment, Bramitob for chronic pulmonary infection management, Foster for asthma treatment, Ixiaro vaccine, Factor IX, and others. Kamada operates in two segments: Proprietary Products and Distribution. It has strategic partnerships with companies like Baxter and markets its products globally.

Panacos Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of small-molecule oral drugs aimed at treating human immunodeficiency virus (HIV) and other viral diseases. Established in 1999 and based in Watertown, Massachusetts, the company utilizes innovative technologies to target specific stages in the viral life cycle, such as virus maturation and fusion. Its product pipeline includes advanced programs centered on HIV maturation inhibition, representing the company's commitment to developing next-generation anti-infective therapies.

NuGEN Technologies specializes in developing and distributing next-generation sequencing (NGS) kits and genomic sample preparation reagents. Established in 2000, the company offers a range of products for DNA and RNA analysis, including solutions for RNA-Seq, targeted resequencing, target capture, ChIP-Seq, Methyl-Seq, and high-throughput applications. NuGEN serves customers globally through its network of distributors, providing robust and reproducible results to advance life sciences research.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

BARRX Medical specializes in developing endoscopic treatment solutions for Barrett's esophagus, a precancerous condition of the esophagus. Its HALO systems use radiofrequency ablation to remove diseased tissue and allow normal cell regrowth. With over 58,000 procedures performed worldwide, BARRX Medical aims to provide effective, non-surgical treatments for patients.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Xillix has develops and commercializes medical imaging technologies for detection and localization of cancer.

Founded in 1993, Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on discovering, designing, and developing therapies for diseases, particularly in the areas of autoimmunity and cancer.

Altimmune is a biopharmaceutical company focused on developing immunotherapies, vaccines, and treatments for liver diseases. Its pipeline includes HepTcell for hepatitis B, NasoShield and AdCOVID for anthrax and COVID-19 respectively, both delivered intranasally, and ALT-801 for non-alcoholic steatohepatitis.